Description
Enclomiphene Research Chemical
Enclomiphene is the trans-isomer of clomiphene citrate, acting as a selective estrogen receptor modulator (SERM). It antagonizes estrogen receptors at the hypothalamus and pituitary, thereby disinhibiting LH and FSH secretion and stimulating endogenous testosterone production. It has been studied in Phase II/III trials for secondary hypogonadism by Repros Therapeutics.
Research Applications
- HPTA axis research: hypothalamic/pituitary ER antagonism and LH/FSH pulsatility
- Secondary hypogonadism models — endogenous testosterone restoration
- SERM selectivity studies — enclomiphene vs zuclomiphene (cis isomer) ER binding profiles
- Comparison with SERMs in hormone receptor pharmacology (tamoxifen, raloxifene, enclomiphene)
Clinical Data Context
Enclomiphene completed Phase III trials (ZA-204, ZA-301) and received FDA Complete Response Letter in 2016. It remains investigational — no approved indication but has the most advanced clinical data of any SERM in testosterone restoration research.
Product Specifications
- Purity: ≥98% HPLC confirmed
- Identity: Mass spectrometry (MW: 405.94)
- CoA: Third-party laboratory, every batch
- Form: Lyophilized powder, sealed glass vial
For Research Use Only (RUO). Not for human consumption.
